Patients’ characteristics
Values are presented as median (range) or number (%). CrCl was estimated by the Cockcroft-Gault equation.
| Characteristic | Patients (n = 108) |
|---|---|
| Age (yr) | 68 (39–82) |
| Male | 79 (73) |
| Height (cm) | 164.4 (143.6–188.1) |
| Body weight (kg) | 59.5 (32.4–92.7) |
| Body surface area (m2) | 1.63 (1.24–2.19) |
| Clinical disease stage (III/IV) | 20 (19)/88 (81) |
| History of platinum-based chemotherapy | 12 (11) |
| Pemetrexed dose (mg/m2) | 497 (427–552) |
| Carboplatin dose (mg⋅min/ml) | 5.21 (4.21–6.60) |
| Combination of bevacizumab | 48 (44) |
| Baseline biologic parameters | |
| WBC (×109/liter) | 6.87 (3.37–23.85) |
| PLT (×109/liter) | 247 (75–508) |
| Hb (g/dl) | 13.2 (8.8–18) |
| CrCl (ml/min) | 73.4 (45.1–156.8) |
| Albumin (g/dl) | 3.9 (3.0–4.7) |
| Coadministration drugs | |
| Lansoprazole | 15 (14) |
| Other PPIs (Esomeprazole/rabeprazole/omeprazole) | 6 (6)/4 (4)/1 (1) |
| NSAIDs | 23 (21) |
| Amlodipine | 15 (14) |
| Hematologic toxicity | 22 (20) |
| Leukopenia | 9 (8) |
| Thrombocytopenia | 20 (19) |
| Anemia | 3 (3) |
CrCl, creatinine clearance; Hb, hemoglobin; NSAIDs, nonsteroidal anti-inflammatory drugs; PLT, platelet; PPI, proton pump inhibitor; WBC, white blood cell.